Accepted Manuscript

Strategic Interaction among Governments in the Provision of a Global Public Good

Margaret K. Kyle, David B. Ridley, Su Zhang

PII:	\$0047-2727(17)30182-2
DOI:	doi: 10.1016/j.jpubeco.2017.10.009
Reference:	PUBEC 3826

To appear in: Journal of Public Economics

Received date:16 December 2016Revised date:16 October 2017Accepted date:30 October 2017

JOURNAL OF PUBLIC ECONOMICS

Please cite this article as: Kyle, Margaret K., Ridley, David B., Zhang, Su, Strategic Interaction among Governments in the Provision of a Global Public Good, *Journal of Public Economics* (2017), doi: 10.1016/j.jpubeco.2017.10.009

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Strategic Interaction among Governments in the Provision of a Global Public $Good^1$

Margaret K. Kyle, MINES ParisTech (CERNA), PSL Research University, and CEPR David B. Ridley, Duke University² Su Zhang, Duke University

Abstract

How do governments respond to other governments when providing a global public good? Using data from 2007-2014 on medical research funding for infectious and parasitic diseases, we examine how governments and foundations in 41 countries respond to funding changes by the US government (which accounts for half of funding for these diseases). Because funding across governments might be positively correlated due to unobserved drivers they have in common, we use variation in the representation of research-intensive universities on US Congressional appropriations committees as an instrument for US funding. We find that a 10 percent increase in US government funding for a disease is associated with a 2 to 3 percent reduction in funding for that disease by another government in the following year. *Keywords:* public goods; free riding; innovation; health; pharmaceuticals

JEL: H4; H5; I18; O1; O3

¹We are grateful for helpful comments from James Anton, Peter Arcidiacono, Ashish Arora, Victor Bennett, Ernst Berndt, Thomas Buchmueller, Thomas Nechyba, Dana Randall, Shannon Seitz, and Ariel Stern, as well as conference and seminar participants at INSEAD, the European Health Economics Association, the International Industrial Organization and Journée de la Chaire Santée at Université Paris Dauphine. Margaret Kyle received support from the Health Chair - a joint initiative by PSL, Université Paris-Dauphine, ENSAE, MGEN and ISTYA under the aegis of the Fondation du Risque (FDR).

²Corresponding author: David Ridley, Fuqua School of Business, Duke University, Durham, NC 27708, david.ridley@duke.edu, +1.919.660.3784.

دريافت فورى 🛶 متن كامل مقاله

- امکان دانلود نسخه تمام متن مقالات انگلیسی
 امکان دانلود نسخه ترجمه شده مقالات
 پذیرش سفارش ترجمه تخصصی
 امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
 امکان دانلود رایگان ۲ صفحه اول هر مقاله
 امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
 دانلود فوری مقاله پس از پرداخت آنلاین
 پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات
- ISIArticles مرجع مقالات تخصصی ایران